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Abstract 
 
Lysosomal storage disorders (LSD) are a family of rare metabolic disorders that include 
Pompe disease and Mucopolysaccharidosis Type 1 (MPS1). Pompe disease is caused by deficiencies 
in the lysosomal enzyme alpha-glucosidase (GAA). This diagnosis is generally divided into infantile 
and late onset, but can exist along a spectrum. The main feature of Pompe disease is progressive 
muscle weakness, and in the infantile onset form, cardiomyopathy is present as well. MPS1 results 
from a deficiency in the lysosomal enzyme alpha-L-iduronidase (IDUA). Features include 
progressive neurological disease, skeletal abnormalities, cardiac disease, corneal clouding, hearing 
loss and hepatomegaly. The diagnosis has been stratified into MPS1 or attenuated MPS1, and 
severity or development of symptoms is dependent on the type. Both Pompe disease and MPS1 were 
recently added to the newborn screening panel. With their addition, a number of challenges have 
occurred including negative psychosocial impact on parents of infants who have an abnormal 
newborn screening result. The purpose of this study was to examine the experience and perceptions 
of parents/caregivers of an infant who had a positive newborn screening result for Pompe disease or 
MPS1.  
A survey was distributed via email and mailer, to parents and caregivers followed by the 
UPMC Children’s Hospital of Pittsburgh and the Children’s Hospital of Philadelphia. The survey 
consisted of questions specific to newborn screening of LSDs. Parent responses, were consistent 
with the literature, indicating that this period was categorized by stress and uncertainty. Of the five 
 v 
respondents, 100% described initial disclosure of the newborn screening results as difficult. 
Responses suggest that negative emotions were fueled by lack of information provided about the 
results, and provider’s lack of knowledge. Similar to published literature, this study indicated the 
majority of infants are not diagnosed with the most severe forms of the disorders. Results of this 
study may have implications for how genetic counselors care for these families and how they 
communicate with other providers. Likewise, it demonstrates public health relevance given the large 
scale in which newborn screening is utilized. This information can be used by providers in their own 
practice and may even influence standard of care.  
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1.0 Introduction 
Lysosomal storage disorders (LSDs) are a group of over 50 rare inborn errors of 
metabolism. These conditions are categorized by impaired lysosome function that typically leads 
to multisystem health manifestations. Of the 50 conditions, two that have been well described are 
Pompe disease and Mucopolysaccharidosis Type 1 (MPS1). In recent years, the development of 
treatment as well as more efficient screening technology have made it possible for early detection 
of these conditions. For this reason, Pompe disease and MPS1 were added to the Recommended 
Uniform Screening Panel (RUSP) in 2015 and 2016.  
Pompe disease, also known as glycogen storage disease type II, is an autosomal recessive 
condition that is estimated to occur in 1/40,000 live births (Hayley, Fragal, & Skrinar, 2003). This 
condition results from variants in the GAA gene, which ultimately leads to impaired functioning 
of the lysosomal enzyme alpha-glucosidase. When this enzyme is not working properly, glycogen 
builds up in the body resulting in multiple health problems (Leslie & Bailey, 2017). Diagnoses are 
categorized into two subtypes, infantile onset (IOPD) and late onset (LOPD). Individuals with 
IOPD have earlier presentations and more severe symptoms. The main systems impacted are the 
musculoskeletal and cardiovascular systems. In addition, patients may also experience respiratory 
complications, macroglossia, failure to thrive, and hepatomegaly (Van den Hout et al., 2003).  
LOPD is distinguished from IOPD by age of diagnosis (over the age of 12 months) as well as 
absent cardiac findings. Clinical features of LOPD are more variable amongst patients. For both 
groups of patients, care should be established with a multidisciplinary team. Likewise, when the 
individual’s phenotype warrants it, initiation of enzyme replacement therapy (ERT) is also 
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recommended (Kishnani et al., 2016). Currently, ERT is the only FDA approved therapy for 
Pompe, however, research options may also be available.  
MPS1 is an autosomal recessive condition that is caused by a deficiency of the lysosomal 
enzyme alpha-L-iduronidase (Clarke, 2002) and is due to variants in the IDUA gene.  The 
incidence of MPS1 is estimated to be 1/100,000 live births (National Organization for Rare 
Disorders). As a result of impaired enzyme activity, an accumulation of glycosaminoglycans 
(GAGs) occurs in the body. In particular, GAG accumulation affects the skeletal system, 
neurologic functioning, cognitive and physical development, hepatic function, vision, and 
cardiovascular system. MPS1 is a highly variable condition and diagnoses are broadly placed into 
one of two categories, MPS1 and attenuated MPS1. In all cases, a multidisciplinary team is needed 
to manage the manifestations of this condition. Approved by the FDA in 2003, ERT has also 
become routine in the care of these patients. In the more severe cases, hematopoietic stem cell 
transplant (HSCT) may be utilized. Individuals may also enroll in research trials studying various 
other treatments such as gene therapy.  
For both MPS1 and Pompe disease, the gold standard for diagnosis is an enzymatic assay 
specific to the deficient enzyme. Earlier detection of these disorders was of interest given that early 
intervention has been shown to improve clinical outcome (Wyatt et al., 2012). Key advancements 
in technology and therapies made it plausible for the addition of Pompe and MPS1 to the newborn 
screen. A key advancement came in 2001 when Chamoles et al. uncovered that lysosomal enzymes 
present in a dried blood spot (DBS) retain their activity. This was the first study that showed it was 
possible to test for lysosomal enzymes in a DBS sample. Finally, in 2015 and 2016 the US 
Secretary of Health and Human Services approved the addition of both conditions to newborn 
screening. The main justifications were the availability of treatment, ability to screen effectively, 
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and proven benefit of early treatment (Bodamer, Scott, & Giugliani, 2017; Donati, Pasquini, 
Spada, Polo, & Burlina, 2018).  Nonetheless, their addition to newborn screening engendered 
controversy because it also elicits the detection of individuals with later onset forms, 
pseudodeficiencies, and variants of uncertain significance. Existing literature examining parental 
impact of newborn screening for Pompe disease and MPS1 is limited. However, studies on a 
variety of inborn errors of metabolism have suggested that the newborn screening period is a time 
of uncertainty and fear for parents (Pruniski, Lisi, & Ali, 2018).  The goal of this study was to 
examine parents’ and caregivers’ experience during the newborn screening period for MPSI and 
Pompe disease. The information gained from this study has the potential to influence the way 
health care providers guide parents through the experience of receiving an abnormal newborn 
screen test result for these two conditions, and potentially other LSDs that are being considered 
for addition to the newborn screening panel. Understanding both the psychosocial and medical 
experience of these parents may allow for more competent care of families.  
1.1 Specific Aims  
Specific Aim 1: Recruit parents and caregivers of children identified through newborn 
screening to be at risk for MPS1 or Pompe disease 
Specific Aim 2: Develop a survey specific for Pompe disease and MPS1 to elicit the 
experiences of parents and caregivers during the newborn screening process   
Specific Aim 3: Use descriptive statistics to analyze and interpret qualitative and 
quantitative data   
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2.0 Literature Review 
2.1 Lysosomal Storage Disorders 
Lysosomal storage disorders (LSDs) are a group of over 50 different metabolic conditions 
that impact the function of the lysosome.  In the general population, the incidence of lysosomal 
storage disorders is approximately 1/7700 live births and the carrier frequency is 1/100. These 
conditions are typically characterized by impaired activity of individual lysosomal enzymes. 
Alternatively, storage disorder phenotypes have also been reported in individuals with defects in 
lysosome biogenesis, impaired receptor activator proteins, defects in the membrane proteins, and 
transporter abnormalities (Parkinson-Lawrence et al., 2010). The altered metabolism leads to a 
build-up of toxic substrate within the cells, which ultimately leads to impaired cellular function 
(National Organization for Rare Disorders; Parkinson-Lawrence et al., 2010).  As a result, 
impairment of multiple organ systems can occur. This literature review aims to focus on two 
particular lysosomal storage disorders, Pompe disease and Mucopolysaccharidosis Type 1, as these 
are the conditions of interest for the study.  
2.1.1 Pompe Disease  
Clinical Features 
Pompe disease, also known as glycogen storage disorder type II, occurs due to a deficiency 
in the lysosomal enzyme alpha-glucosidase (GAA), which results in the buildup of glycogen in 
the body (Leslie & Bailey, 2017). It is estimated that the incidence of Pompe is 1/40,000 live births 
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(Hayley et al., 2003). Phenotypes are quite variable, however, two broad categories of diagnoses 
exist, infantile (IOPD) and late-onset (LOPD). The diagnoses are distinguished by age of onset, 
severity of symptoms, organs impacted, and the rate of progression (Kishnani et al., 2016).  
The infantile form of the disease is typically characterized by an onset within the first 
months of life and cardiac impairment (Angelini & Semplicini, 2011).  If glycogen build up is 
significant enough, then cardiac hypertrophy may begin in utero and continue to progress 
postnatally. Eventually, the excessive accumulation leads to cardiomegaly with subsequent left 
ventricular thickening (Hayley et al., 2003). Another key feature is the onset of progressive muscle 
weakness within the first four months of life (Kishnani et al., 2006). Infants with IOPD typically 
present with severe hypotonia or generalized muscle weakness. When left untreated, the muscles 
of the body will become progressively weaker, which can impede motor development and 
ambulation. Muscle weakness can also lead to complications such as difficulty breathing, impaired 
cough, feeding difficulties, blood gas abnormalities, and sleep apnea. Feeding difficulties are 
common in this patient population, and as a result, about 53% of patients have failure to thrive 
(Kishnani et al., 2006).  Approximately 29% of patients with IOPD present with hepatomegaly 
and macroglossia (Van den Hout et al., 2003). Macroglossia may also contribute to airway 
obstruction and feeding difficulties (Staretz-Chacham, Land, LaMarca, Krasnewich, & Sidransky, 
2009).  
LOPD is characterized by onset any time between childhood to adulthood. This form of 
the disease is slowly progressive and clinical phenotypes tend to be much more variable. In both 
LOPD and IOPD the systems that are impacted are similar, however, the major distinction is the 
absence of cardiac findings in LOPD patients. The main clinical features include, proximal muscle 
weakness, respiratory complications, and delayed motor milestones. (Hayley et al., 2003).  
 6 
Respiratory manifestations are common, occurring in approximately 1/3 of LOPD patients. 
Recurrent respiratory infections, and sleep-disordered breathing may be early manifestations of 
LOPD (Confalonieri et al., 2019).  Failure to properly treat respiratory findings may lead to 
respiratory failure and subsequent early mortality (Merk, Wibmer, Schmann, & Hruger, 2009).  
Molecular Basis 
Pompe disease is caused by pathogenic variants in the GAA gene, which is located on 
chromosome 17 at 17q25.3. GAA, is responsible for coding the lysosomal enzyme acid alpha-
glucosidase (U.S. National Library of Medicine). The gene contains 20 exons and spans a length 
of 20 kb (Dennis, Moran, & Healy, 2000; Giancarlo Parenti et al., 2013). Over 300 pathogenic 
variants have been identified in the GAA gene.  One of the most common variants is the deletion 
of exon 18 c.2482_2646del (Ngiwsara et al., 2019). Many variants are common to various ethnic 
groups. The most common pathogenic variant in the Caucasian population with a frequency of 
47% is c.-32-13T>G (Kroos et al., 1995). In the African American population, the most common 
IOPD variant is the R854X variant (c.2560C>T; p.Arg854Ter) (Becker et al., 1998). In the 
Taiwanese population, Ko et al.1999 were able to identify 7 different pathogenic variants by 
studying 11 unrelated families (Ko et al., 1999). The most commonly occurring were the p.D645E 
(p.Asp645Glu), p.G615R (p.Gly615Arg), and c.1411del4 (p.Glu471-shift).  
Inheritance and Recurrence risk 
Pompe disease is an autosomal recessive condition. For an individual to be affected, they 
must be homozygous or compound heterozygous for two disease-causing variants.  In the event 
that each member of a heterosexual couple is a carrier for Pompe they would have a 25 % chance 
of having a child who is affected with the condition.  
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Genotype/ Phenotype correlation 
While a clear genotype/phenotype correlation has yet to be established for Pompe, 
generally, individuals who are homozygous for null variants which will produce no alpha-
glucosidase activity have an infantile presentation (Hoefsloot LH, 1990).  In comparison, patients 
with LOPD usually have a combination of pathogenic variants that lead to residual enzyme activity 
(Confalonieri et al., 2019). Nonetheless, variability of symptoms and presentation continues to 
pose a challenge to the effort of establishing a clear genotype/phenotype correlation. Multiple 
pathogenic variants have been reported in both forms of the conditions. For example, the exon 18 
deletion has been reported in both LOPD and IOPD (Hule et al., 1994).  In 2005, Wens et al. 
performed a study in which they identified 22 Dutch families comprised of two or three siblings 
diagnosed with Pompe disease (Wens et al., 2013).  Of those 22 families, 11 of the sibling sets 
displayed a large variation in phenotype. This included a set of siblings in which one of the siblings 
was ventilator and wheelchair dependent and the other ambulant with no need for a ventilator. 
Notably, as well, 12 families with a shared genotype (c.-32-13T>G/c.525delT) had individuals 
who presented as infants and some who presented later in life.  
Diagnosis  
The standard method for diagnosing Pompe disease is enzyme activity testing with the use 
of an assay. This testing approach has become popular due to the inexpensive cost, minimally 
invasive nature, and accuracy of results. The assay can be run on various samples including a dried 
blood spot, leukocytes, and fibroblasts. In the case of LOPD, muscle biopsies are sometimes used 
as a tool for diagnosis (Muscumeci, 2019), although if Pompe disease is included as part of the 
differential diagnosis then enzyme testing is less invasive. Molecular testing of the GAA gene can 
also be useful. (Leslie & Bailey, 2017).   
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Management and Treatment  
Treatment of Pompe disease entails the involvement of a multidisciplinary team.  Along 
with standard medications for heart disease and nutrition, initiation of enzyme replacement therapy 
is recommended when the individual’s symptoms warrant it. In 2006 the American College of 
Medical Genetics (ACMG) published standard guidelines for treatment of patients (Kishnani et 
al., 2016). For infantile patients, care should be established with the following specialists: 
cardiology, pulmonology, neuromuscular, and a metabolic geneticist.  Assessment of cardiac 
disease should begin with a baseline echocardiogram and electrocardiogram (EKG). Subsequent 
cardiac management may include the use of chest x-rays and various heart medications, such as 
ACE inhibitors. Other medications may exacerbate cardiac symptoms, and thus should be 
cautiously used. Respiratory function should be assessed regularly, both when the patient is awake 
and asleep.  Testing such as gas exchange and chest radiographs may be utilized for this purpose. 
Infections should be treated aggressively in both LOPD and IOPD given the high risk for severe 
respiratory complications. Annual monitoring of neuromuscular disease is another important 
component of management. Progression of disease can be assessed using nerve conduction studies 
as well as electromyography (EMG) and developmental scoring.  
Enzyme replacement therapy (ERT) was first approved for IOPD in 2006, and then later 
again in 2010 for LOPD. Commercially known as Myozyme™ (initially and outside of the US) 
and Lumizyme™ (same product but utilizes a larger bioreactor), the drug itself is a recombinant 
form of the human alpha-glucosidase enzyme (alglucosidase alfa). The drug is administered to the 
patient intravenously and is used to replace the absent or deficient enzyme so that it breaks down 
the accumulated glycogen and prevents future build up in the body.  Response to the therapy tends 
to vary among patients since effectiveness of the treatment depends on a multitude of factors 
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including the clinical picture of the individual (Desai et al., 2018). Alternative therapies as well as 
therapies to use alongside ERT are under investigation given that ERT is not curative and response 
is variable (Bellotti et al., 2020). Another current therapy under study is chaperone therapy. This 
therapy is of particular interest given that chaperones have high bioavailability, can cross the blood 
brain barrier, and can be administered orally (Parenti, Generoso, & Valenzano, 2015). Kishnani et 
al. in 2017 conducted a phase II study in which they administered a chaperone (Duvoglustat) to 
individuals with Pompe (Kishnani et al., 2017). They found that after administration of both 
Duvoglustat and ERT increased total GAA activity, specifically muscle GAA activity, was 
increased.   
While gene therapy is not yet available clinically for patients with Pompe disease, multiple 
studies are being conducted to study the efficacy of gene therapy as a potential treatment. The 
treatment would consist of the administration of a gene delivery vector into the bloodstream, 
muscle, or other tissues (Ronzitti, Collaud, Laforet, & Mingozzi, 2019). A study performed by 
Han et al. in 2019 utilized gene therapy on both adult and infant mouse models. Both the infant 
and adult mice showed significant improvement in both muscle tone and cardiac disease. 
Moreover, both sets of mice in the study showed biochemical correction, however these findings 
were much more significant in the adult population (Han et al., 2019).  Lastly, due to the fact that 
there are nonsense variants in GAA known to be associated with Pompe, stop codon read through 
therapy has been considered, however, there is no evidence suggesting efficacy in treating Pompe 
(Bellotti et al., 2020).  
Prognosis 
Without intervention, the prognosis of individuals with IOPD is poor, with death occurring 
before the age of one. The most common cause of mortality in these patients is cardiac and/or 
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respiratory failure (Kishnani et al., 2009).  In recent years, however, the introduction of ERT has 
changed Pompe disease outcomes. IOPD patients who receive ERT within the first few weeks of 
life have shown improvement in all clinical features including respiratory, cardiac, and muscle 
function. A study by Yang et al. (2016) found that patients who began treatment early were found 
to have lower levels of anti-rh acid alpha-glucosidase, antibodies indicating long-term 
effectiveness as a treatment method (Yang et al., 2016).  Likewise, ERT administration over the 
course of multiple years has shown to reduce mortality and morbidity. Kishnani et al (2009) 
conducted a study in which 18 infants diagnosed with infantile Pompe disease were administered 
infusions of alglucosidase alfa every other week while being monitored over the course of three 
years (Kishnani et al., 2009).  Results showed that the overall risk of death was decreased by 95% 
and risk for ventilation was reduced by 91%.  Furthermore, ERT was found to improve 
cardiomyopathy and a majority of the patients maintained significant motor skills.  In the case of 
LOPD, prognosis is more variable based on the severity of the disease. Typically, individuals with 
LOPD, who have experienced the disease for longer periods of time, have diminished quality of 
life and a shorter life span (Chan et al., 2017).  Similar to IOPD, studies since 2010 have shown 
that adults with preexisting symptoms who are placed on ERT show significant improvement. In 
particular, ERT has a positive impact on respiratory function as well as laboratory markers (Merk 
et al., 2009).   
2.1.2 Mucopolysaccharidosis Type 1 
Clinical Features  
Mucopolysaccharidosis Type 1 (MPS1), also known historically as Hurler/Hurler-
Scheie/Scheie syndrome, is due to a deficiency in the lysosomal enzyme alpha-L-iduronidase 
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(Clarke, 2002).  This enzyme is responsible for the breakdown of glycosaminoglycans (GAGs) in 
the body. Four categories of GAGs exist including, heparan sulfate, dermatan sulfate, keratan 
sulfate, and hyaluronan (Zhang, Zhang, & Linhardt, 2010). GAGs are thought to play a role in cell 
signaling (Casale & Crane, 2019). When there is not enough enzyme or it is not functioning 
properly, GAGs accumulate in the body and lead to significant health problems. Specifically, in 
individuals with MPS1, dermatan sulfate and heparan sulfate accumulate. The estimated incidence 
of MPS1 is approximately 1/100,000 live births (National Organization for Rare Disorders). At 
birth, infants usually do not present with any features but over time will present a progressive 
neurologic decline or worsening of physical features throughout childhood. Based on severity and 
age of onset, the diagnosis was historically classified into one of three broad categories, Hurler, 
Hurler-Scheie, and Scheie.  Currently, however, it is organized/categorized into MPSI and 
attenuated MPSI. 
The most severe form of the disorder referred to as MPS1 (MPS1-H). This form of the 
condition is characterized by early onset of neurological disease and death before the age of 10 
(Matter et al., 2002).  The effects of neurological disease typically appear around 12-24 months in 
the form of developmental delay. Early development may appear appropriate, however, skill 
development will usually cease and neurological decline will commence shortly after (Muenzer, 
Wraith, Clarke, & International Consensus Panel on the Managment and Treatment of 
Mucopolysaccharidosis, 2009).  Hydrocephalus is another feature that may contribute to delayed 
neuromotor development. A patient’s clinical course is also complicated by dysostosis multiplex. 
These skeletal findings can include a large skull, enlarged J-shaped sella, short stature, and 
deformities of the spine as well as the pelvis (Wendel, 2003).  Corneal clouding is also noted in 
the majority of patients. Typically this clouding is progressive, which leads to severe visual 
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impairment (Clarke, 2002). Furthermore, most individuals have some degree of cardiac 
involvement. Most commonly, the GAG accumulation in the heart leads to thickening of the aortic 
and mitral valve (Wendel, 2003). Progression of cardiac findings and early-onset dementia are 
often contributors to mortality. Other common features include, coarse facial features, 
hepatomegaly, and hearing loss. 
Attenuated phenotypes are categorized by a later age of onset and absent or mild 
intellectual disability (Terlato & Cox, 2003).  The organ systems affected can be similar to MPS1-
H, but the presentation and severity can be more variable.  
Molecular Basis 
MPS1 is caused by pathogenic variants in the IDUA gene, which is located on chromosome 
4p16.3. IDUA is responsible for the production of the lysosomal enzyme alpha-L-idurondase. The 
gene contains 14 exons that span 19 kb (H. S. Scott, Giuo, Hopwood, & Morris, 1992). There have 
been 170 disease-producing pathogenic variants identified in the IDUA gene (Beesley et al., 2001). 
In the Caucasian population, the p.W402X and p.Q70X are two common pathogenic variants that 
account for 60% of disease alleles (Bunge et al., 1995).  Other common pathogenic variants include 
p.P533R and p.L490 (Bunge et al., 1995; Gatti et al., 1997).  
Inheritance and Recurrence risk 
MPS1 is an autosomal recessive condition. For an individual to be affected with this 
condition, they must be homozygous or compound heterozygous for two disease-causing variants. 
In the event that each individual in a heterosexual couple are carriers for MPS1, their offspring 
would have a 25% chance of being affected.   
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Genotype/phenotype correlation  
Genotype/phenotype correlations are not well established for MPS1. However, recent 
analysis of the MPS1 registry has identified some correlations.  In general, nonsense variants as 
well as variants that drastically disrupt protein function have been associated with little to no 
enzyme activity. Individuals who are homozygous or compound heterozygous for these types of 
pathogenic variants usually present with a more severe phenotype (Clarke et al., 2019). Both the 
p.W402X and p.Q70X variants are associated with absent enzyme activity. However, these 
variants have been identified in individuals with an attenuated phenotype as well. In most cases, 
these individuals were compound heterozygous for one of these null variants as well as a missense 
variant (Clarke et al., 2019).  Missense variants tend to be associated with residual enzyme activity. 
The most common variants associated with an attenuated phenotype are p.P533R and p.L490. The 
p.P533R variant has been reported in individuals with variable disease severity (Terlato & Cox, 
2003).  This variability in phenotype is common in the presence of missense variants, and thus 
they continue to pose a challenge for prognosis and counseling.   
Diagnosis 
An enzyme assay for alpha-L-iduronidase is the standard method for diagnosis of MPS1. 
This testing can be performed on cultured fibroblasts, isolated leukocytes, or dried blood spot 
cards. Although not diagnostic, urine studies are often used in the evaluation process to measure 
the amount of GAG accumulation that is present. Individuals with MPS1 will usually have higher 
levels of GAGs in their urine due to the defective enzyme activity (Cleary & Wraith, 1995; Sanofi 
Genzyme, 2017). Molecular analysis of the IDUA gene is also available for diagnostic purposes.  
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Management and Treatment 
Management of MPS1 requires a multidisciplinary team to attend to the clinical 
manifestations of the disease.  In addition to standard clinical care for each of the organ systems, 
enzyme replacement therapy is also available for administration when clinical manifestations 
warrant it. In more severe cases individuals may also undergo a hematopoietic stem cell transplant. 
The ACMG guidelines published in 2009 recommend that patients with MPS1 have evaluations 
from the following specialists: cardiology, ophthalmology, orthopedics, audiology, neurology, and 
gastroenterology (Muenzer et al., 2009).  Evaluations should continue every 6-12 months to 
monitor disease progression. Annual neurology evaluations should include imaging of the brain 
and spine in addition to monitoring of head circumference. If hydrocephalus is suspected, then a 
lumbar puncture should be considered in order to evaluate cerebral spinal fluid pressure.  When a 
patient is experiencing headaches or abnormal sleep behavior, shunting may alleviate these 
symptoms as well as the intracranial pressure. While cognitive impairment is typically recognized 
between 12-24 months, a baseline neurocognitive evaluation is warranted in order to monitor for 
decline. Developmental stimulation in early stages of the disease can also be helpful for retention 
of skills. Respiratory management is another important component. Patients with MPS1 are at 
increased risk for respiratory insufficiency. Pulmonologists should be consulted in order to guide 
treatment. In some cases, a tonsillectomy and/or adenoidectomy may be helpful, however, in 
severe cases a tracheostomy may be performed as a lifesaving method.  An orthopedic surgeon 
should address skeletal manifestations of the disease.  Surgery may be an option when skeletal 
deformities are detected early. These surgeries may include, spine fusions, osteotomy for hip 
dysplasia, and carpal tunnel release. Regardless of surgical status, physical therapy is 
recommended for maintenance of joint function and muscle strength.  
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The FDA approved enzyme replacement therapy with laronidase (brand name: 
Aldurazyme™) in 2003.  The drug is a recombinant form of the human alpha-L-iduronidase and 
is administered intravenously.  Recommended dosage for patients is 0.58 mg/kg on a weekly basis 
(Genzyme, 2010).  When administered, the recombinant enzyme promotes the breakdown of 
GAGs as well as prevents further build up. Long-term administration has been shown to reduce 
the levels of urine GAGs and improves non-CNS manifestations (Wraith et al., 2004).  Although 
there are benefits, the therapy does have limitations. ERT does not remedy the cognitive or 
neurological manifestations due to the fact that it does not cross the blood-brain barrier (Muenzer 
et al., 2009). Variations of ERT as well as alternative administration sites have been suggested in 
order to address this limitation. One alternative therapy suggested, which is similar to current 
practice, is intravenous ERT with fusion proteins. This therapy is another recombinant form of 
alpha-L-idronidase, however, the fusion protein has been modified so that the IgG domain targets 
blood barrier transporters (Kubaski et al., 2020). In 2018, Giugliani et al. studied the effects of the 
IgG-IDUA fusion protein (valanafusp alpha) on pediatric patients with MPS1 (Giugliani et al., 
2018).  Throughout the trial, researchers noted improvements of urine GAGs, liver and spleen 
volumes, and shoulder range of motion. This data suggested that the fusion protein is transported 
across the blood brain barrier, and thus has potential to improve neurological disease. Intrathecal 
administration of ERT has also been explored as a means to address cognitive impairment. 
Recently, studies have focused on the intrathecal administration used in conjunction with 
intravenous ERT and hematopoietic stem cell transplant (HSCT). In 2019, Eisengart et al. found 
that when all three methods were administered together there was a decrease in disease biomarkers, 
and increase in cognitive function (Eisengart et al., 2019 ).  
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In more severe cases, enzyme replacement therapy is used in combination with HSCT.  
HSCT alone has been shown to improve multi-system functioning, however, guidelines 
recommend the use of both ERT and HSCT for maximal efficacy and improved outcomes.  The 
use of ERT administered before transplant has been shown to reduce mortality associated with 
HSCT due to the fact that ERT generally improves symptoms (Wynn et al., 2009).  
A number of novel gene therapies are under investigation for MPS1. The therapy would 
involve the delivery of the IDUA gene to the patient via a vector. The theory is that the 
administration of the deficient gene would be able to address the health concerns that current 
therapies cannot address such as the neurological deterioration. Studies using MPS1 mice and gene 
therapy have resulted in increased IDUA activity as well as improved lysosomal function, 
indicating clinical effectiveness, and potential to translate to human disease (Schuh et al., 2018). 
Stop codon read through has also been suggested as a possible therapy given the prevalence of 
nonsense variants in certain populations (Kubaski et al., 2020). However, studies on various 
models have yet to prove any efficacy of this therapy (Kamei et al., 2014).  
Prognosis  
Historically, prognosis for patients with MPS1 (MPS1-H) has been poor. Unfortunately, 
even with the introduction or ERT and HSCT to the management of these patients, death still 
usually occurs within the first 10 years of life (Clarke, 2002; Zhou, Lin, Leung, & Wang, 2020). 
Mortality is most commonly a result of cardiorespiratory failure and progressive neurological 
disease (Muenzer et al., 2009). Combination therapy has been associated with a decrease in 
morbidity as well as enhanced (Eisengart et al., 2013; Eisengart et al., 2018). Patients with the 
attenuated form of the disease have a more variable outcome given the clinical variability seen 
amongst patients. 
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2.2 Newborn Screening 
Newborn screening refers to the testing that each newborn undergoes during their first few 
days of life.  It is a public health intervention for all newborns in the US in which the goal is to 
initiate treatment early for life threatening health conditions in order to decrease morbidity 
(Bradford et al., 2015). The work of Robert Guthrie led to the development of newborn screening 
in the 1960’s.  In his work as a microbiologist, Guthrie developed a bacterial inhibition assay used 
to study purine and pyrimidine metabolites. He was able to utilize this technology to detect 
phenylalanine, which lead to early detection of Phenylketonuria (PKU) (Pitt, 2010). Early 
detection was integral to the management of PKU because it allowed for regulation of 
phenylalanine intake before the excess of phenylalanine led to intellectual disability and other 
health problems caused by PKU.  The utility of the screen was quickly realized, and many state 
newborn screening programs commenced during the 1960’s.  
2.2.1 Methods of Testing 
In the United States, the newborn screen consists of multiple tests.  Although this screen is 
used to detect individuals with various conditions, it is just a screening test. Further evaluations 
are necessary following an abnormal screen result to confirm a diagnosis. A hearing test is part of 
newborn screening. The test utilizes audiometry to assess the newborn’s hearing. This test follows 
a two-stage protocol; all newborns are tested in the first stage and then for those who have failed 
the first stage they are tested again (Welzl-Mueller, 2001).  Infants are also tested for congenital 
heart disease through the use of pulse-oximetry (Koppel et al., 2003).  Through this method, 
oxygen saturation is measured in the blood in order to identify low levels of oxygen (Seelback-
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Gobel, 2014). An abnormal test could indicate the presence of congenital heart disease.  Lastly, 
the Guthrie card is utilized to screen for a variety of other conditions with known interventions.  
Typically, a heel stick is performed 48-72 hours after the infant is born and the blood is blotted 
onto a special card (Pitt, 2010).  The sample is then analyzed using high performance liquid 
chromatography and/or tandem mass spectrometry (Wilcken, Wiley, Hammond, & Carpenter, 
2003).  This technology allows for the detection of metabolites in order to screen for various 
disorders such as inborn errors of metabolism (Fernandez-Lainez, Aguilar-Lemus, Vela-Amieva, 
& Ibarra-Gonzalez, 2012). This technology also allows for states to regulate which conditions they 
screen for. This is due to the fact that technology detects the metabolites by their specific mass and 
displays the results on a mass spectrum. Different metabolites can be blinded based on what each 
state has chosen to include in their screening panel.  
2.2.2 Criteria for Newborn Screen 
In 1968, Wilson and Jungner developed a set of criteria that would be used to establish 
guidelines for screening.  Their goal was to guide the selection of conditions based on the ability 
to detect the condition in the early stages and the availability of treatment (Andermann, 
Blancquaert, Beuchamp, & Dery, 2007).  Recently, the criteria have been updated in order to 
accommodate for advancement in technology.  In 2006, the ACMG established basic principles to 
be used as a framework when creating criteria to evaluate conditions (Watson, Mann, Lloyd-
Puryear, Rinaldo, & Howell, 2006).  The criteria were divided into three main categories: (1) 
clinical characteristics of the conditions, (2) analytical characteristics of the screening test, and (3) 
diagnosis, treatment, and management. After their analysis, they identified 31 core conditions, or 
conditions in which screening should be mandated.  
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In the United States, it is the responsibility of each state to determine which conditions are 
included on newborn screening. However, the Recommended Uniform Screening Panel (RUSP) 
was adopted nationally as an effort to standardize the newborn screen across the country (National 
Institute of Child Health and Human Development).  First developed in 2003 by the Advisory 
Committee on Heritable Disorders and the ACMG, the RUSP is the list of disorders that are 
recommended to be included on each state’s newborn screen (Advisory Committee on Heritable 
Disorders in Newborns and Children, 2006). Currently, there are 35 conditions listed on the RUSP. 
The list has been organized into five main categories of disorders: hemoglobinopathies, organic 
acid disorders, amino acid disorders, fatty acid oxidation disorders, and miscellaneous disorders 
(American College of Obstetricians and Gynecologists, 2015).  Based on the ACMG guidelines, 
for a condition to be added to the newborn screen it must at minimum meet the following three 
criteria: detection of the condition can occur within 24-48 hours of birth, there is an accurate test 
that is sensitive and specific, and there is benefit to early initiation of treatment (National Institute 
of Child Health and Human Development).  
2.2.3 Lysosomal Storage Disorders and Newborn Screening 
The recent addition of LSDs to the newborn screen was made possible by advancements 
in technology as well as treatment. In the past, limitations in knowledge of the natural history, 
treatment, and reliable testing methods made first tier screening unfeasible (Schielen, Kemper, & 
Gelb, 2017).  In 2001, a significant breakthrough occurred when Chamoles and his colleagues, 
uncovered that lysosomal enzymes in a dried blood spot sample retain their activity (Chamoles, 
Blanco, & Gaggioli, 2001).  Using fluorescence, they were able to successfully quantify enzyme 
activity in Fabry patients. Tandem mass spectrometry (MS/MS), a key advancement in newborn 
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screening, is an effective strategy for identifying LSDs via newborn screening.  MS/MS utilizes 
specialized technology to electronically measure the mass of various molecules. The first 
successful use of MS/MS in the identification of a lysosomal enzyme was in 2005 by Wang et al.  
Subsequent studies using MS/MS for the detection of lysosomal enzymes reported positive 
predictive values as high as 95%, which supported the addition of LSDs to routine newborn 
screening (Scott et al., 2013). Advancements in therapies in the last two decades have also 
influenced the decision to include LSDs on newborn screening. Specifically, treatment with ERT 
has significantly impacted the natural history of these conditions. Longitudinal studies of patients 
treated with ERT provided evidence that early initiation as well as long-term treatment resulted in 
better clinical outcomes (Wyatt et al., 2012).  Findings, such as these highlighted the importance 
of early detection and reinforced the need for appropriate screening.  
2.2.3.1 Pompe  
The addition of Pompe disease to the RUSP was first suggested by the ACHDNC in 2013, 
and then approved by the US Secretary of Health and Human Services in 2015.  The key 
justifications for the approval was the availability of enzyme replacement therapy and that its early 
initiation has proven benefits (Bodamer et al., 2017).  In addition to treatment, the committee also 
determined that the addition of Pompe disease would have beneficial public health impact. Experts 
estimated that in the US each year, the newborn screen would identify 144 infants with the disease, 
which could prevent 19 deaths per year (US Secretary of Health and Human Services, 2015).  
Nonetheless, the addition of Pompe disease was controversial and remains that way today. 
Concerns related to screening for Pompe stems mainly from inevitable detection of individuals 
with late-onset Pompe disease, those with pseudodeficiencies or variants of unknown significance, 
and inability to predict reliably the onset of symptoms. Debate still surrounds the best course of 
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action for this cohort of individuals found to have LOPD, pseudodeficiencies, and VUS. However, 
the detection by newborn screen has the potential to save the patient from a diagnostic odyssey 
(Pruniski et al., 2018).  
2.2.3.2 MPS1 
The addition of MPS1 to the newborn screen was first proposed in 2015 and then approved 
by the US Secretary of Health and Human Services in 2016.  Inclusion of MPS1 was supported as 
a result of evidence indicating that early initiation of enzyme replacement therapy with laronidase 
(Aldurazyme™) improves clinical outcome as well as biomarkers (Donati et al., 2018). From a 
public health perspective, it was determined that screening all newborns in the US would detect 
about 44 infants with MPS1 per year, and prevent two deaths before 5 years of age each year (US 
Secretary of Health and Human Services, 2016). Parents of these children were also in support of 
the addition of MPS1 to the newborn screen. A study conducted by de Ru et al. in 2012 revealed 
that parents experienced considerable distress caused by delay in their child’s diagnosis (de Ru, 
Bouwman, WIjburg, & van Zwieten, 2012). While these parents acknowledged the risks, the 
majority felt that the benefit of early diagnosis and treatment outweighed those risks. Nonetheless, 
challenges that were considered in this study have come about as a result of screening infants for 
MPS1. With a wide clinical spectrum, prediction of severity and onset remains difficult to 
determine. Another concern is the identification of variants of uncertain significance and 
pseudodeficiencies. Each of these cases can result in undue psychological and financial burden for 
the family (Parini et al., 2018). For this reason, the addition of MPS1 to newborn screening has 
not been without controversy.  
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2.2.3.3 Pilot Studies  
Since the addition of LSDs to the newborn screen, multiple pilot studies have been carried 
out in order to assess whether or not they are suitable as part of the newborn screen. In the United 
States, New York conducted a pilot study in which they reported the data from the newborn 
screening of 65,000 infants, making it one of the largest studies performed (Wasserstein et al., 
2019). The study focused on five lysosomal storage diseases: Pompe, Fabry, Niemann Pick A/B, 
Gaucher, and MPS1.  In the sample of 65,000 infants, sixty-nine positive screens were identified. 
Of the sixty-nine positive screens, twenty-three were found to be a true positive result. Further 
analysis of the twenty-three infants revealed that all were at risk for a late-onset presentation or 
had pseudodeficiency variant(s). Specifically, in the cohort identified to be at risk for Pompe 
disease, they found one late-onset patient, two heterozygote carriers, and three infants who were 
pseudodeficient. In the cohort identified to be at risk for MPS1, there were thirteen individuals. 
Four were heterozygote carriers and eight were pseudodeficient or had a benign variant. Based on 
this data, the researchers determined that newborn screening for lysosomal storage diseases is 
feasible, however, screening is more likely to identify infants at risk for late-onset disease and 
carriers than those who are affected with the more severe early onset disease.  
2.2.3.4 Impact on Families  
While there is limited literature available about the impact of newborn screening for LSDs 
on parents, a number of studies have been conducted on the impact of screening for other metabolic 
conditions. Parents who have gone through the newborn screening process report increased levels 
of stress, long-term concern for the health of their child, and uncertainty regarding what the 
screening results meant for their own health (Waisbren et al., 2003).  Interviews conducted via a 
single site study of thirty families revealed that the feelings of distress began with the initial shock 
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of receiving the abnormal results (DeLuca, Kearney, Norton, & Arnold, 2011). These feelings then 
carried through the entirety of the process and were exacerbated while waiting for the results of 
the diagnostic testing. Of note, some parents when asked to recall details of the child’s condition 
even reported back inaccurate information. Similar findings were reported in a 2018 study in which 
parents of children diagnosed with Pompe disease were interviewed (Pruniski et al., 2018). The 
two most common themes amongst parents were uncertainty and fear.  Parents of infants diagnosed 
with late-onset Pompe were particularly prone to this reaction when thinking how to best care for 
asymptomatic children. When asked about their overall view of newborn screening, parents of 
infants diagnosed with IOPD reported being grateful that their child was diagnosed early. On the 
other hand, parents of infants diagnosed with LOPD either felt that the screen prevented a future 
diagnostic odyssey for their child or that their child was a “guinea pig.” Another concern is the 
impact of false positive results on parents. Currently, the specificity of the screen overall is poor 
and ability to establish a positive predictive value is difficult given the rarity of LSDs (Baerg et 
al., 2018). These problems can lead to costly follow up testing as well as psychological burden to 
the parents (Baerg et al., 2018). Studies have shown that false positive test results cause negative 
effects on parents both short term and long-term (Hewlett & Waisbren, 2006). Parents interviewed 
for a study in 2006 by Gurian et al. reported that stress level increase during the follow up testing 
needed in light of an abnormal screen. This study also suggested that false positives have an impact 
on how parents care for the child in the future. Children who received false positive results had 
twice as many hospitalizations for a variety of childhood symptoms as compared to children whose 
newborn screening did not result in a false positive (Gurian, Kinnamon, Henry, & Waisbren, 
2006). Studies have suggested improvements to second tier testing as well as alternative metrics 
to amend this concern (Baerg et al., 2018; Gelb, 2018). These studies outline that understanding 
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the psychological impact is a vital component to care. Expanding health care providers 
understanding of the family’s experience will allow for optimal care and adaptation as more infants 
are identified to be at risk for Pompe or MPS1 via newborn screening. 
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3.0 Manuscript 
3.1 Background 
Lysosomal storage disorders (LSD) constitute a group of over 50 metabolic disorders, with 
an approximate incidence of 1/7700 in the general population. Most often, these conditions are 
characterized by impaired lysosomal enzyme function. Less commonly, LSD phenotypes can 
result from biogenesis of the lysosome, impaired receptor activator proteins, deficits in the 
membrane proteins, and defects with transporters (Parkinson-Lawrence et al., 2010; R. Wang, 
Bodamer, Watson, & Wilcox, 2013).  The defect in lysosomal function leads to an accumulation 
of toxic substrates in the cells, which ultimately impairs intracellular and extracellular function. 
As a result, multiple organ systems such as the cardiovascular, nervous, and musculoskeletal 
systems become compromised.  
Pompe Disease 
Pompe disease, also known as glycogen storage disorder type II, is an autosomal recessive 
condition with an estimated incidence of 1/40,000 (Hayley et al., 2003).  This condition is caused 
by pathogenic variants in the GAA gene that lead to a deficiency in the lysosomal enzyme alpha-
glucosidase (GAA) (U.S. National Library of Medicine). Deficiencies in this enzyme result in 
glycogen build up in the body (Leslie & Bailey, 2017). Pompe disease is divided into two 
categories, infantile (IOPD) and late onset (LOPD).  Diagnosis is differentiated based on age of 
onset, severity of symptoms, organ involvement, and rate of progression (Kishnani et al., 2016).  
Both IOPD and LOPD are diagnosed via an enzyme assay. Sequencing of the GAA gene can also 
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be performed for diagnostic purposes, and in the event that sequencing of GAA only reveals one 
pathogenic variant, deletion/duplication analysis may follow (Leslie & Bailey, 2017). Molecular 
analysis may also be warranted to confirm diagnoses in cases of LOPD (Kishnani et al., 2016).  
IOPD is characterized by an onset of symptoms within the first few months of life and 
significant cardiac impairment, specifically cardiomegaly (Angelini & Semplicini, 2011). 
Additionally, the muscles of these infants are significantly impacted.  Hypotonia or generalized 
muscle weakness becomes apparent within the first 4 months of life (Kishnani et al., 2006).  
Progressive muscle weakness can lead to breathing difficulty, issues with feeding, and sleep apnea. 
Other symptoms associated with IOPD are macroglossia, failure to thrive, and hepatomegaly (Van 
den Hout et al., 2003).  Management for patients involves a multidisciplinary team as well as the 
utilization of enzyme replacement therapy (ERT). Care should be established with cardiology, 
pulmonology, neurology, and a clinical geneticist (Kishnani et al., 2016).  
LOPD is characterized by onset of symptoms anytime between childhood to adulthood.  
Infants with LOPD may also present with symptoms, but the diagnosis is distinguished from IOPD 
by of the lack of cardiac involvement. While the majority of systems impacted in LOPD are similar 
to that of IOPD, clinical features are more variable in this group of patients. Generally, common 
features of LOPD include proximal muscle weakness, respiratory complications, and delayed 
motor milestones (Hayley et al., 2003). Similar to patients with IOPD, management for LOPD 
patients includes a multidisciplinary team and ERT (Kishnani et al., 2016).  
Mucopolysaccharidosis Type 1 
Mucopolysaccharidosis Type 1 (MPS1) is a condition that is caused by a deficiency of the 
lysosomal enzyme alpha-L-iduronidase (Clarke, 2002). It is estimated to occur in approximately 
every 1/100,000 live births (National Organization for Rare Disorders).  The condition is caused 
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by pathogenic variants in the IDUA gene, and is inherited in an autosomal recessive manner. When 
alpha-L-iduronidase is not functioning properly, glycosaminoglycans (GAGs) accumulate in the 
body, which ultimately leads to a variety of health problems. Due to the variability in phenotypes, 
MPS1 diagnoses have been divided into two broad categories, MPS1 and attenuated MPS1 
(MPS1-H, MPS1-HS, MPS1-S). An individual’s disease is placed into one of these categories 
based on severity of symptoms and age of onset (Clarke, 2002).  
The most severe form of the disorder is MPS1 (MPS1-H). Typically individuals who fall 
into this category have early onset of neurological disease between 12-24 months. (Matter et al., 
2002). With the attenuated forms, MPS1-HS and MPS1-S, neurological disease is typically 
diagnosed later in life or not at all (Terlato & Cox, 2003). Other hallmarks of MPS1 include, 
corneal clouding, dysostosis multiplex, coarse facial features, hepatosplenomegaly, hearing loss, 
and recurrent ear, nose, and throat infections. A diagnosis of MPS1 is often made using an enzyme 
assay specific to alpha-L-iduronidase.  Individuals with MPS1 usually have higher traces of GAGs 
in the urine, and thus a urine analysis can be used as a screening tool (Cleary & Wraith, 1995). 
Molecular analysis of the IDUA gene is also available and should be part of the diagnostic work-
up for patients. Management entails a multidisciplinary team. In 2009 the ACMG published 
guidelines that recommended individuals with MPS1 establish care with cardiology, 
ophthalmology, orthopedics, audiology, neurology, and gastroenterology (Muenzer et al., 2009). 
Enzyme replacement therapy and hematopoietic stem cell transplant (HSCT) are also established 
treatment approaches for MPS1.  
Newborn Screening  
Developed by Robert Guthrie in 1963, newborn screening refers to the testing that nearly 
every newborn in the US undergoes within the first 48-72 hours of life (Pitt, 2010). The ACMG 
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and the Advisory Committee of Heritable Disorders developed criteria that a condition must meet 
at a minimum in order to be considered for the RUSP. These include: (1) detection of the condition 
can occur within 24-48 hours of birth, (2) there is an accurate test that is sensitive and specific, 
and (3) there is benefit to early initiation of treatment (National Institute of Child Health and 
Human Development). The US Secretary of Health and Human Services approved the addition of 
Pompe disease to the RUSP in 2015 and the addition of MPS1 in 2016. For both conditions, the 
main justification in favor of the addition was the availability of FDA approved therapies, proven 
benefits of early administration, and ability to screen effectively (Bodamer et al., 2017; Donati et 
al., 2018).  Nonetheless, controversy still surrounds the addition of these conditions (Peake & 
Bodamer, 2017; Wasserstein et al., 2019). The screening is sensitive, and because of this, it has 
detected individuals with late-onset forms of these conditions, pseudodeficiencies, and variants of 
uncertain significance. While the debate currently continues regarding the best means of care for 
this cohort, there is a general consensus that screening for Pompe disease and MPS1 has the 
potential to save individuals from long diagnostic odyssey and improves clinical outcomes 
(Pruniski et al., 2018).  
Parent and caregiver experience with newborn screening for various conditions has been 
explored in the literature in regards to inborn errors of metabolism (DeLuca et al., 2011; Pruniski 
et al., 2018).  However, literature related to LSDs is limited. One study conducted by Pruniski et 
al. (2018), interviewed parents of children identified to be at risk for Pompe disease by newborn 
screening. Parents reported that fear and uncertainty about their child’s health defined this time 
period. The goal of this study was to expand our knowledge and understanding of parents’ and 
caregivers’ experience with newborn screening.  To achieve this goal, a survey was constructed to 
elicit various aspects of parents’/caregivers’ experience, with a focus on the psychosocial impact. 
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Providers may use the results of this study to guide families through the complicated process of 
receiving an abnormal newborn screening result. Understanding the psychosocial impact on 
families may allow genetic counselors to better tailor their interactions to alleviate some of the 
emotional burden parents may experience. The results of this study may inform the way healthcare 
providers manage families as more infants are identified to be at risk.  
3.2 Methods 
3.2.1 Participants  
The population of interest for this study were parents and caregivers, 18 years and older, 
who have infants identified to be at risk for Pompe disease or MPS1 via newborn screening. Before 
recruiting commenced, the study was approved by the University of Pittsburgh Institutional 
Review board (IRB) (Appendix A). The main study site was the UPMC Children’s Hospital of 
Pittsburgh. Recruiting sites included the UPMC Children’s Hospital of Pittsburgh as well as the 
Children’s Hospital of Philadelphia. Families were identified at each institution via patient 
databases kept by the lysosomal storage disorders teams at each respective facility. At the UPMC 
Children’s Hospital of Pittsburgh, parents and caregivers were contacted via email or mailer. Only 
an email was distributed by the Children’s Hospital of Philadelphia to their families. Both the 
email and mailer were abbreviated versions of the formal consent located at the beginning of the 
survey. Both documents outlined that the survey was optional, there were no benefits to 
participating, minimal risk was associated with participation, information was collected 
anonymously, and there was no compensation for participating. The email then concluded with the 
 30 
link to the survey, which the participant could click, and contact information for the lead 
researcher. The mailer contained the link to the survey, which the recipient would have to type in 
to their browser of choice in order to participate. Similar to the email, the mailer concluded with 
the contact information for the lead researcher. Formal consent was obtained directly at the 
beginning of the document prior to the start of the survey. The consent outlined in further detail 
the information in the email and mailer as well as described the study in more detail. Participants 
then had the option to select “Yes, I would like to participate” or “No, I do not wish to participate”. 
If they chose “yes,” then they were directed to the survey and if “no” was chosen, then they were 
taken to the end of the survey.  Non-responses were categorized as “no,” or not included in the 
dataset.   
3.2.2 Survey Development  
The survey consisted of 28 questions. Participants accessed the survey through a single 
web link. The survey was developed using the Qualtrics survey platform and consisted of five 
main sections. The first section developed by the lead researcher consisted of multiple-choice 
questions pertaining to demographics as well as questions about physical processes the parents and 
caregivers went through during this specific period of time. The second and third portion of the 
survey utilized a Likert scale. The questions in these portions were adapted from interview 
questions developed for a study by DeLuca et al. in 2011. The questions from the interview were 
modified to be specific for Pompe disease as well as MPS1. The fourth section of the survey 
consisted of an adapted version of the Perceived Stress Scale. Permission to use the scale was 
given by the lead developer of the scale, Sheldon Cohen (Appendix B). Questions in this section 
were adapted to pertain more specifically to stress related to the newborn screening process. The 
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last section of the survey was an open-ended question for the participants to add any comments 
about their experience which they did not feel was captured by the survey The survey used skip 
logic as well as branching in order to personalize the survey based on which condition the 
respondent’s child was identified to be at risk for. A clinical geneticist, two genetic counselors, 
and a researcher with expertise in survey development reviewed the survey. (Appendix F). 
3.2.3 Data Collection  
The survey was open to participants from February 21st, 2020 to March 21st, 2020. Access 
to the survey was through a web link given to participants via an email or mailer. A reminder was 
sent to families on March 6th. Data was collected anonymously through the Qualtrics system.  
Utilizing Microsoft Excel, descriptive statistics were performed on the data collected from 
the survey. Given the response rate, data specific to each condition was not analyzed separately. 
Responses were analyzed using Microsoft Excel. Since the Perceived Stress Scale was modified 
to fit the aims of this study, the scale developed to evaluate the original stress scale was not used 
for this specific data analysis. Instead a similar process was used to interpret the data in which an 
answer of “yes” was given 2 points, “sometimes” was given 1 point, and “no” was given 0 points. 
In the case of questions 2, 3, and 6 the scores were reversed to account for the positive statements. 
All questions were answered in full, so there was no need to remove partial responses.  
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3.3 Results 
3.3.1 Demographics  
The survey was distributed to approximately 40 families cared for by UPMC Children’s 
Hospital of Pittsburgh or Children’s Hospital of Philadelphia. The survey was distributed to 
families who had at least one infant identified to be at risk for Pompe disease or MPS1 by newborn 
screening. Of the estimated 40 families, five responded resulting in a response rate of 12.5%. Each 
participant completed the survey in full. The first set of questions asked the participants to identify 
their relationship to the child, what condition the child was identified to be at risk for, and if they 
had had any previous children with the same partner (Table 1). Of the 5 participants, 60% (n=3) 
had infants identified to be at risk for Pompe disease and 40% (n=2) had infants who were 
identified to be at risk for MPS1. Every participant identified themselves as the mothers of these 
children, with the average age being 34.8 years and a standard deviation of 5.1 years. Additionally, 
100% (n=5) of participants identified themselves as Caucasian (Table 7, Appendix G). Education 
levels varied between all the participants. Each individual reported a different level of education 
including, an associate degree, some college, 4-year college degree, doctorate degree, and trade 
school (Table 7, Appendix G). The majority of the participants, 60%, had previous children with 
the same partner while 40% (n=2) reported that this was the first child between them and their 
partner (Table 1). 
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Table 1 Demographics 
3.3.2 Disclosure of Final Newborn Screening Results 
3.3.2.1 Details of Disclosure  
Participants answered questions that pertained to receiving the newborn screening results 
for the first time. The majority of patients reported that they had heard about newborn screening 
prior to receiving the results. Participants were asked how they were first told about the final 
newborn screening results, and 100% reported that they were told over the phone (Table 2). Three 
(60%) out of the 5 participants were first told about these results by the child’s primary care 
physician (PCP), while the other 2 (40%) were told about the results by a genetic counselor (Table 
2).  
 
 
 
Variable  Number of participants n=5 
Condition  
Pompe  60% (3) 
MPS1 40% (2) 
Relation to Child   
Mother  100% (5) 
Father  0% (0) 
Grandparent  0% (0) 
Other  0% (0) 
Any previous children with the same 
partner  
Yes 60% (3) 
No 40% (2) 
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Table 2 Results Disclosure 
 
3.3.2.2 Perception of Newborn Screening Results Disclosure  
Participants answered Likert scale questions that addressed their experience receiving the 
newborn screening results for the first time (Table 8, Appendix G). For both groups, questions 
were similar except when asked if the participants had heard of the particular condition that their 
child was identified to be at risk for. The majority of respondents (80%) strongly disagreed with 
this statement. When asked to respond to the statement, “It was difficult hearing the results of the 
newborn screen for the first time”, 80% (n=4) strongly agreed while the other 20% (n=1) agreed  
(Table 3).  In response to “I understood what the results meant for my child’s health”, answers 
were much more variable; 20% (n=1) strongly disagreed, 20% (n=1) disagreed, 20% (n=1) neither 
agreed nor disagreed, 40% (n=2) agreed (Table 3). Lastly when asked about the information the 
participants received from their provider, 40% (n=2) indicated that they strongly agreed that their 
Variable  Number of participants 
n=5 
First provider to disclose the results of the 
final NBS results 
 
Primary Care Physician (PCP)  60% (3) 
Genetic Counselor  40% (2) 
Geneticist  0% (0) 
Means by which you were told about the 
final NBS results 
 
During a doctors appointment  0% (0) 
Over the phone  100% (5) 
Other  0% (0) 
Had you heard about newborn screening 
prior to this experience? 
 
Yes 80% (4) 
No 20% (1) 
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provider could have given them more information during that initial contact, while another 40% 
(n=2) agreed with the same statement (Table 3).   
Table 3. Parent Perception 
 
 
 
 
 
 
 
 
 
 
 
3.3.3 Initial Genetic Appointment and Diagnosis  
3.3.3.1 Diagnoses  
Urine and lab studies were used to determine the diagnoses of the infants. In the cohort of 
participants who had infants identified to be at risk for Pompe disease, 100% (n=3) of the parents 
self-reported that their infants were diagnosed with LOPD (Figure 1). Of the participants whom 
Variable  Number of participants n=5 
I knew what Pompe/MPS1 was before this process  
Strongly Agree 0% (0) 
Agree 20% (1) 
Neither agree nor disagree 0% (0) 
Disagree 0% (0) 
Strongly Disagree 80% (4) 
It was difficult hearing the results of the newborn screen 
for the first time 
 
Strongly Agree 80% (4) 
Agree 20% (1) 
Neither agree nor disagree 0% (0) 
Disagree 0% (0) 
Strongly Disagree 0% (0) 
I feel like the health care provider who first told me the 
results could have given me more information 
 
Strongly Agree 40% (2) 
Agree 40% (2) 
Neither agree nor disagree 20% (1) 
Disagree 0% (0) 
Strongly Disagree 0% (0) 
I understood what the results meant for my child’s 
health 
 
Strongly Agree 0% (0) 
Agree 40% (2) 
Neither agree nor disagree 20% (1) 
Disagree 20% (1) 
Strongly Disagree 20% (1) 
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had children identified to be at risk for MPS1, 50% (n=1) self-reported their child had a VUS and 
the other 50% (n=1) self-reported being unclear about their child’s results (Figure 1).  
 
 
Figure 1 Confirmed Diagnoses 
3.3.3.2 Perceptions and Actions Post Genetics Appointment  
Likert scale questions were utilized to elicit information about the participants experience 
after the initial genetics appointment (Table 9, Appendix G). Participants were first asked to 
indicate what level they agree with the following statement, “I was relieved after the initial genetics 
where the screening results were discussed”.  Of the 5 participants, 20% (n=1) strongly disagreed, 
20% (n=1) disagreed, 20% (n=1) neither agreed no disagreed, and 40% (n=2) agreed (Figure 7). 
Participants all agreed (100%, n=5) that waiting for the results of the urine/lab tests was stressful 
(Table 9, Appendix G). In response to the statement, “I changed the way I cared for my child 
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during this time period”, 40% (n=2) of participants strongly agreed, 20% (n=1) neither agreed nor 
disagreed, 20% (n=1) disagreed, and 20% (n=1) strongly disagreed (Table 4). 
 
Table 4 Parent Perception and Actions 
3.3.4 Perception of Newborn Screening 
The last two questions of this section aimed to capture participants’ overall perception of 
their experience (Table 10, Appendix G). Answers varied among participants to the statement, 
“After my experience, I have a positive view of the newborn screening experience.” Forty percent 
(n=2) of participants strongly disagreed, 20% (n=1) neither agreed nor disagreed and 40% (n=2) 
agreed (Table 5). However, when asked to what extent they agreed or disagreed with the statement, 
“I believe disorders similar to MPS1 and Pompe disease should be added to the newborn screen,” 
100% (n=5) strongly agreed (Table 10, Appendix G).   
 
 
Variable  Number of participants n=5 
I was relieved after the initial genetics appointment 
where the screening results were discussed 
 
Strongly Agree 0% (0) 
Agree 40% (2) 
Neither agree nor disagree 20% (1) 
Disagree 20% (1) 
Strongly Disagree 20% (1) 
I changed the way I cared for my child during this time  
Strongly Agree 40% (2) 
Agree 0% (0) 
Neither agree nor disagree 20% (1) 
Disagree 20% (1) 
Strongly Disagree 20% (1) 
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Table 5 Parent Perception of Newborn Screening 
3.3.5 Stress Scale  
A modified version of the Perceived Stress Scale was utilized for the survey. Participants 
were asked to answer, “yes”, “sometimes”, or “no” to a variety of statements in order to capture 
stress levels during the newborn screening process (Table 11, Appendix G) The maximum score 
that a participant could receive was a 22 while the minimum score was a 0. Participant scores 
ranged from 4 to 21. The average score amongst the participants was a 13.2 with a standard 
deviation of 7.56 (Table 6).  
Table 6 Stress Scale Scores 
Participant Total Score  
#1 4 
#2 9 
#3 21 
#4 21 
#5 11 
Average ±SD 13.2 ±7.56 
Range (scores) 4-21 
Variable  Number of participants n=5 
After my experience, I have a positive view of the 
newborn screening experience  
 
Strongly Agree 0% (0) 
Agree 40% (2) 
Neither agree nor disagree 20% (1) 
Disagree 0% (0) 
Strongly Disagree 40% (2) 
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3.4 Discussion 
Although statistical analysis could not be performed due to the limited number of 
participants, this study provided insight into aspects of the experience these parents underwent 
with newborn screening.  
3.4.1 Demographics 
The demographics of the participants in this study are similar to the study conducted by 
Pruniski et al. in 2018. In their study, all participants were mothers and identified as Caucasian. 
The majority of participants in both studies reported that this was not their first child. Likewise, 
education levels varied amongst the participants. Overall, based on the literature and patient 
populations at the recruitment sites, these demographics were expected. More diversity in 
respondents was desired due to the fact that a study by Catz et al. (2005), suggested that cultural 
orientation, education, and historical influence can impact the was individuals respond and process 
genetic information (Catz et al., 2005). Newborn screening is am intervention that is utilized for 
all populations, and because of this understanding the perspective and needs of different groups of 
individuals is important for holistic care.   
3.4.2 Disclosure of Final Newborn Screening Results  
3.4.2.1 Details of Disclosure  
The majority of the participants in this study had prior knowledge of newborn screening. 
This finding is not consistent with other previous studies that focused on similar topics (Davis et 
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al., 2006; DeLuca et al., 2011).The results of several studies have suggested that more in depth 
education could lessen the stress these parents experience (Kemper, Fant, & Clark, 2005; Waisbren 
et al., 2003). While the participants in this study had previous knowledge of newborn screening, 
expanding on their understanding may also lessen the emotional burden. The majority of the 
participants in this study as well as in the study performed by Pruniski et al. (2018) reported that 
the child’s PCP was the first provider to disclose the results of the newborn screen. Other studies 
that focused on cystic fibrosis and sickle cell anemia also suggest that the PCP’s are the main 
source of information for these families at the time of the disclosure (Collins et al., 2012).  This 
finding highlights the importance of additional education for these providers. Being more informed 
may give more confidence to the provider when disclosing these results to parents and in turn 
allow them to counsel these families to the fullest extent.    
3.4.2.2 Perception of Newborn Screening Results Disclosure  
This section of the survey aimed to elicit how the participants felt during the initial 
disclosure of the screening results and their perception of the provider who disclosed the results. 
Responses to this study were congruent with the results of the study performed by DeLuca et al. 
(2011) in that most of the participants in both studies had no knowledge of the disorder that their 
child was identified to be at risk for by newborn screening (DeLuca et al., 2011). LSDs are rare 
disorders, and therefore, it is expected that these families would not have experience. The majority 
of our participants also reported that in that moment they did not understand what the results meant 
for their child’s health and that they felt like the provider who disclosed the screening results could 
have given them more information. Many participants turned to the Internet, which only fueled 
their concern.  In 2006 Kemper et al. performed a study in which they interviewed PCP’s and 
family medicine providers. Responses to their study suggested that PCP’s are not prepared for all 
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aspects of newborn screening follow up (Kemper, Uren, Moseley, & Clark, 2006).  Responses to 
the last portion of this study only reinforced their sentiments. In the final section of the survey 
participants were given the options to provide further comments. One participant commented that 
when she asked the nurse about Pompe disease, the provider responded, “It’s something that 
involves the muscles.” Another participant responded saying, “Having my PCP call me with the 
results but not being able to provide me with additional information is insane.” PCPs may benefit 
from educational resources that would potentially allow them to provide parents with more 
accurate information to better prepare them for the future. Better quality information may also give 
the parents a better understanding of what the result means for their child’s health, which may aid 
in alleviating stress.  
3.4.3 Initial Genetics Appointment and Diagnosis  
3.4.3.1 Diagnoses 
Similar to a pilot study performed in New York City (Wasserstein et al., 2019), none of 
our participants reported that their children were diagnosed with IOPD or MPS1 (MPS1-H). A 
study performed by Tang et al. (2006) in California, estimated that the birth prevalence of 
individuals with IOPD is lower than in other regions, but the rate of LOPD is higher (Tang et al., 
2020). Results such as these reinforce that children with LOPD will continue to be identified as 
more infants are screened in the United States and that the frequency of Pompe disease (especially 
LOPD) is likely to change. Likewise, more parents will continue to experience stress related to 
their child’s newborn screen results. Understanding factors, such as lack of information, that are 
stressors for these parents may allow for optimal care and guidance. Pretest counseling may be 
explored as a means to prepare parents. As discussed in the study by Pruniski et al. (Pruniski et 
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al., 2018) with children being diagnosed with LOPD and later onset MPS1, parents experience 
uncertainty about their child’s future medical needs. Follow up, proper counseling, education, and 
resources could be beneficial for these families, as it has been shown that these can help parents 
adjust to uncertainty (Wang, 2020).   
3.4.3.2 Attitude and Actions Post Genetics Appointment  
All the participants reported that the period in which they waited for the results of the 
confirmatory testing was incredibly stressful. While one parent reported feeling reassured by the 
initial genetics appointment, two (40%) of the participants reported that they did not. Although 
providers tell parents that confirmatory testing may be negative, parents may still feel stress and 
anxiety until results confirm the information given to them by the genetics team (Wang, 2020). 
Even when the results do confirm the provider’s initial diagnosis, some parents may still not feel 
relief. One parent in our study reported that, “It was a very stressful time and I am still scared. My 
son will be 3 in April and while I believe we determined him to be a carrier with pseudo symptoms, 
I do not know for sure because I do not have the other parent to be tested.” Together, these highlight 
the importance of proper counseling and provision of resources, which may aid in the parent’s 
stress and coping.  
3.4.4 Perception of Newborn Screening 
An interesting finding from this study is that all participants (100% n=5) agreed that LSDs 
should be on newborn screening even though they had different reactions to the newborn screening 
process. This positive perspective of newborn screening for LSDs is consistent with prior research 
that explored perceptions of parents who have undergone newborn screening. Parents tend to look 
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favorably upon screening, especially if there is benefit to early treatment (Catharina Plass, van El, 
Pieters, & Cornel, 2009; Pruniski et al., 2018). Despite the challenges faced by these parents, they 
have lower stress levels and are better able to cope as compared to parents whose children were 
not diagnosed by newborn screening (Waisbren, Rones, Read, Marsden, & Levy, 2004). These 
results suggest that parents see benefit in an early diagnosis and that it may play a role in helping 
parents cope.  
3.4.5 Stress Scale  
All the participants in this study reported some degree of stress, however, the range in 
scores was relatively large spanning from 4-21. The highest score that could have been attained 
was a 22. This range of scores demonstrates how the needs of families can vary even in similar 
situations, and that proper understanding of those needs is important for their care. The parent who 
scored 4, reported feeling relieved after the appointment with the genetics providers, and it is 
possible that having a knowledgeable provider can be useful in relieving stress for these parents. 
One participant in this study stated, “After meeting with the providers at Children’s Hospital, many 
of my fears and worries were relieved.” Other studies note that parents search for information in 
this time period and are willing to find providers who can answer their questions (Salm, Yetter, & 
Tluczek, 2012).   
Although the number of respondents was low, it is still notable that 40% (n=2) of the 
parents reported relatively high levels of stress during the entirety of the newborn screening 
process. These two individuals reported “Yes” to many of the items on the stress scale, outlining 
the impact this process has on many aspects of these parents’ life. These parents reported feeling 
that they did not feel on top of things in their life and had trouble sleeping, both things that could 
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lead to lasting psychological impact. Studies have suggested that timely return of results and 
psychosocial intervention could be useful for relieving stress and anxiety (DeLuca et al., 2011; 
Tluczek, Koscik, Farrell, & Rock, 2005).  
3.4.6 Study Limitations 
This study had several limitations, with the most important being the low response rate. 
This low number of participants did not allow for any inferential statistical analysis that could 
provide information on statistically significant results. While the results provided information on 
the experiences of these parents, the inability to assess the significance of these results means that 
the conclusions cannot be made for all parents who have undergone this process. The limited 
number may also be attributed to how long the survey was available to potential participants. The 
window for response was a month, so more time may have been warranted. The use of mailers as 
a recruitment tool may have also been a barrier given the extra step required to access the survey 
instead of being immediately available via a link in the email. Finally, recruitment from Children’s 
Hospital of Philadelphia (CHOP) was compromised due to COVID-19. Correspondence between 
the lead researcher and genetic counselors at CHOP occurred March 11th, 2020 and on March 16th, 
2020 the situation with COVID-19 increased in severity. In that time frame, the governor of 
Pennsylvania issued a stay at home order. This meant that individuals were required to stay 
indoors, and many professionals were required to work from home. This major adjustment, made 
it increasingly difficult to recruit individuals for this study, and unfortunately led to loss of 
correspondence with CHOP. As a result, no participants were recruited from this site, contributing 
to the small sample size.   
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Another limitation to this study is the demographics of the participants. All the participants 
identified themselves as the mother of the child and therefore, the study was not able to capture 
the impact this experience had on other caregivers/parents. A goal of the study was to obtain 
responses from different caregivers. However, given that mothers tend to be the main gatekeeper 
for a family’s healthcare, it is not unexpected that respondents were mothers (Case & Paxson, 
2001). In addition, all the participants identified themselves as Caucasian, and thus this study lacks 
data on the experience of other populations. Participant diversity was another goal when designing 
this study, however, the patient population at UPMC Children’s Hospital of Pittsburgh LSD 
program is predominantly Caucasian. To increase diversity, the Children’s Hospital of 
Philadelphia was added as a recruitment site.   
An additional limitation to this study was the design itself. This study was retrospective, 
mainly recruiting individuals who have already undergone the newborn screening process. The 
goal was to capture the experience of parents who had undergone and who are currently going 
through this experience. Data is limited on the needs of parents currently in the process and further 
exploring these parents’ experience has the potential to expand providers’ knowledge of how to 
best meet parents’ needs.  
3.4.7 Future Directions 
This study reinforces the findings of previous research regarding parent perceptions of 
newborn screening (DeLuca et al., 2011; Wang, 2020), while also providing additional information 
specific to LSDs. The number of participants was low and therefore, a continuation of this specific 
project would provide more data. As more infants are screened for LSDs, future research may also 
focus on comparing retrospective and prospective experiences of several parents and caregivers. 
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Results from these studies could give insight into different aspects of the parent experience, 
possibly revealing areas where improvement to the process is needed. Because all the participants 
in this study were mothers, studies could be carried out that specifically target other family 
members/caregivers. This could give a more holistic understanding of the impact of the newborn 
screening process for LSDs on the family system.  
A number of studies have been carried out to obtain recommendations from parents who 
have undergone newborn screening and received an abnormal result (Salm et al., 2012; Wang, 
2020). One study conducted by Raymond Wang (2020) examined Pompe disease. The research 
collected qualitative data from parents of children who were identified to be at risk for Pompe 
disease via newborn screening. Parents were able to voice their concerns in the hope that providers 
can utilize it. Studies like this can be easily translated to other LSDs including MPS1. Collecting 
qualitative data will continue to be important in order to understand the unique experience of these 
families, especially because of the rarity of these disorders. Information from these studies could 
then inform the ways in which health care providers manage and counsel these parents.  
Lastly, further research specific to non-genetics providers who are disclosing newborn 
screening results is warranted. The study by Kemper et al. in 2006, gave excellent insight into the 
perspective of the PCPs (Kemper et al., 2006).  Their study consisted of 350 PCPs and family 
physicians. Of their respondents, the majority agreed that the PCP should be the one to disclose 
the results of the positive newborn screen. However, multiple respondents indicated that they did 
not have the knowledge to discuss the conditions of the newborn screening panel. Interviews such 
as these could be conducted in order to evaluate the knowledge these providers have specific to 
LSDs. Qualitative information such as this has the potential to give insight to the disparities of 
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providers. Providers can utilize this information to improve their own practice and potentially seek 
resources for themselves and their families.  
3.5 Conclusion 
There is a paucity of literature that describes the experience of parents who have had infants 
identified to be at risk for LSDs by newborn screening. This study provides insight into the 
experience of parents whose children received an abnormal newborn screening test for Pompe 
disease or MPS1, and hopefully encourages future research that furthers understanding of parents’ 
experiences with newborn screening. Results of the study are consistent with prior research. As in 
previous studies, the results indicate that the newborn screening process is characterized by stress 
and uncertainty for parents. The ranges in stress levels highlight that while these parents are 
undergoing the same process, the needs of parents are not the same. While the sample size in the 
study was small, the reported diagnoses are similar to the findings of the New York pilot study 
(Wasserstein et al., 2019). No guardians of infants identified with the most severe form of either 
Pompe disease or MPS1 responded to this survey. As more newborns are found to have later onset 
forms of the conditions, pseudodeficiencies, or variants of uncertain significance, understanding 
the impact of receiving these results will be crucial for offering anticipatory guidance for families. 
While controversy regarding the addition of LSDs to the newborn screen persists, this study has 
shown that parent support newborn screening for LSDs. All participants strongly agreed that LSDs 
should be included in newborn screening. Lastly, responses from the participants indicate that 
there is a gap in the knowledge of these disorders amongst non-genetics providers. Because these 
providers might be the main source of information for these families, they need to be well informed 
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of these conditions in order to provide parents with appropriate medical information. As more 
LSDs are added to the newborn screen and more infants are screened for these conditions, it will 
become imperative for providers to understand the experience of parents in order to address the 
unique needs of this population.  
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4.0 Research Significance to Genetic Counseling and Public Health 
Although the results of this study cannot be used to make generalizations about the 
population of parents who receive abnormal LSD result on newborn screening, they can be utilized 
by genetic counselors that provide care for these parents. Both management guidelines for Pompe 
disease and MPS1 recommend the involvement of genetic counselors at time of the diagnosis 
(Kishnani et al., 2016; Muenzer et al., 2009). As a health care provider involved in the care of 
these families, it is important that genetic counselors have an understanding of the psychological 
and emotional impact of receiving an abnormal newborn screening result. Given their unique 
psychosocial skill set, genetic counselors can use this information in order to address the 
psychological needs of these parents. Recognizing how parents respond to the abnormal result and 
its disclosure can guide how genetic counselors share the diagnosis and provide education about 
the condition. Finally, given the disparity in the knowledge of LSDs amongst primary care 
providers (Kemper et al., 2006), genetic counselors could play a role in developing educational 
programs for these providers.  
Newborn screening is a public health program that routinely screens 4 million babies each 
year for a variety of conditions (Moreno, 2016).  Its goal is to detect infants with congenital 
conditions before they are symptomatic in order to initiate treatment early and hopefully lessen the 
long-term burden of the condition (Pitt, 2010). The Center for Disease Control, estimates that 
12,500 newborns will be diagnosed with a condition from the newborn screening panel each year, 
which means that 1/300 newborns are diagnosed with a core condition (National Institute of Child 
Health and Human Development, 2017).  When analyzed from the perspective of the three core 
functions of public health, policy development and assurance are particularly relevant (Center for 
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Disease Control and Prevention, 2011). Currently as it stands, there is no standard policy regarding 
parental consent.  It not a crucial factor in newborn screening, and approaches differ from region 
to region (Pelias & Markward, 2001). As screening becomes more advanced and more conditions 
are added to screening panels, new models for informed consent for newborn screening may be 
worth exploring. A study performed by Ulph et al. (2020), utilized focus groups to examine 
provider and parent perspective of informed consent for newborn screening (Ulph, Dharni, 
Bennett, & Lavender, 2020). The study was conducted in London where informed consent is 
obtained for newborn screening. The focus group consisted of parents as well as screening 
professionals, which included hospital screening coordinators, midwives, and quality assurance 
managers.  Responses indicated both parents and screening professionals value informed consent, 
but recognize the challenges in obtaining it, including training those who obtain the DBS cards 
and privacy concerns. A consent process could offer anticipatory guidance to these families, which 
may make lessen the emotional burden should they receive an abnormal result. Potentially, a model 
could be proposed which the states could use to regulate the consent process. Having at minimum 
a model to follow may make the process more attainable for providers.  
One of the main components of assurance is to, “assure a competent environmental health 
work force”(Center for Disease Control and Prevention, 2011), which this study aimed to gain 
information that providers could utilize in order to provide more comprehensive care for these 
parents. This study identified areas in which these parents felt there were gaps in their care, such 
as the provider’s lack of knowledge, and lack of information given to them regarding the newborn 
screening result. Knowing these issues, providers can hopefully fill these gaps and create an 
effective standard of care.   
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Appendix G Supplemental Figures 
 
Table 7 Additional Demographic Information 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable  Number of participants n=5 
Race  
White  100% (5) 
Black or African American  0% (0) 
American Indian of Alaska Native 
American  
0% (0) 
Asian  0% (0) 
Native Hawaiian or Pacific 
Islander  
0% (0) 
Other  0% (0) 
Prefer not to respond 0% (0) 
Education   
Some High-School or GED 0% (0) 
High-School Diploma  0% (0) 
Associate Degree 20% (1) 
Some College  20% (1) 
College 4 year degree 20% (1) 
Masters Degree 0% (0) 
Doctorate Degree 20% (1) 
Other  20% (1) 
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Table 8. Perception Toward Newborn Screening Results Disclosure 
 
 
 
 
 Strongly 
Disagree 
Disagree Neither agree 
nor disagree 
Agree Strongly Agree 
I was unaware that 
my child had 
newborn screening  
3 (60%) 1 (20%) 1 (20%) 0 (0%) 0 (0%) 
It was difficult 
hearing the results of 
the newborn screen 
for the first time  
0 (0%) 0 (0%) 0 (0%) 1 (20%) 4 (80%) 
I knew what 
MPS 1 was before 
this process 
1 (50%) 0 (0%) 0 (0%) 1 (50%) 0 (0%) 
I knew what Pompe 
disease was before 
this process 
3 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
I felt the need to look 
up more information 
after receving the 
final results of the 
newborn screen 
0 (0%) 0 (0%) 0 (0%) 1 (20%) 4 (80%) 
I understood the 
information I was 
given by the health 
care provider about 
the final newborn 
screening results  
0 (0%) 1 (20%) 1 (20%) 3 (60%) 0 (0%) 
I understood what 
the results meant for 
my child’s health  
1 (20%) 1 (20%) 1 (20%) 2 (40%) 0 (0%) 
I feel like the health 
care provider who 
first told me the 
results could have 
given me more 
information  
0 (0%) 0 (0%) 1 (20%) 2 (40%) 2 (40%) 
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Table 9 Perception Post-Genetics Appointment 
 
 
 
Table 10 Perception of Newborn Screening 
 Strongly 
Disagree 
Disagree Neither agree 
nor disagree 
Agree Strongly Agree 
After my experience, I 
have a positive view of 
the newborn screening 
experience  
2 (40%) 0 (0%) 1 (20%) 2 (40%) 0 (0%) 
I believe disorders 
similar to MPS1 and 
Pompe disease should 
be added to the 
newborn screen  
0 (0%) 0 (0%) 0 (0%) 0 (0%) 5 (100%) 
 
 
 
 
 
 Strongly 
Disagree 
Disagree Neither agree 
nor disagree 
Agree Strongly Agree 
I was relieved after the 
initial genetics 
appointment where the 
screening results were 
discussed  
1 (20%) 1 (20%) 1 (20%) 2 (40%)        0 (0%) 
It was stressful waiting 
for the results of the 
lab/urine tests ordered 
by genetics to confirm 
my child’s diagnosis  
0 (0%) 0 (0%) 0 (0%) 0 (0%) 5 (100%) 
I changed the way I 
cared for my child 
during this time 
1 (20%) 1 (20%) 1 (20%) 0 (0%) 2 (40%) 
I felt the need to follow 
up with genetics after 
receiving the lab/urine 
results 
0 (0%) 1 (20%) 1 (20%) 0 (0%) 3 (60%) 
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Table 11 Stress Scale 
 Yes           Sometimes No 
During the newborn screening 
process I felt stressed 
4 (80%) 0 (0%) 1 (20%) 
During the newborn screening 
process I felt confident in my ability to 
handle my personal problems 
2 (40%) 1 (20%) 2 (40%) 
During the newborns screening 
process I felt things were going my 
way  
0 (0%) 3 (60%) 2 (40%) 
During the newborn screening 
experience I could not cope with all 
the tasks I had to do 
2 (40%) 1 (20%) 2 (40%) 
During the newborn screening 
process I could not control irritations 
in my life 
2 (40%) 0 (0%) 3 (60%) 
During the newborn screening 
process I felt on top of things  1 (20%) 2 (40%) 2 (40%) 
During the newborn screening 
process I was often angered by things 
outside my control  
1 (20%) 1 (20%) 3 (60%) 
During the newborn screening 
process I had trouble sleeping  2 (40%) 2 (40%) 1 (20%) 
During the newborn screening 
process I often spoke with my child’s 
medical team 
 
1 (20%) 
 
 
2 (40%) 
 
 
2 (40%) 
 
During the newborn screening 
process I thought about my child 
being different from others  
 
4 (80%) 
 
1 (20%) 
 
0 (0%) 
During the newborn screening 
process I worried about long-term 
impact of the condition  
 
4 (80%) 
 
1 (20%) 
 
0 (0%) 
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